Table 2.
Comparative analysis between groups
| ULR < 0.049 | ULR > 0.049 | P | |
|---|---|---|---|
| No. of patients (%) | 232 (79%) | 62 (21%) | – |
| Age (y) | 64.34 (± 7.08) | 67.6 (± 6.05) | 0.001 |
| Body mass index (kg/m2) | 27.16 (± 3.6) | 26.29 (± 3.5) | 0.097 |
| TURS volume(cc) | 40.75 (± 21.6) | 39.9 (± 24.3) | 0.792 |
| Prior TURP | 12 (6%) | 6 (9.7%) | 0.312 |
| DRE abnormal | 137 (60.6%) | 38 (62.3%) | 0.812 |
| PSA (ng/mL) | 12.43 (± 14.2) | 17.7 (± 54.6) | 0.453 |
| Hemoglobin (mg/mL) | 14.89 (± 1.03) | 14.4 (± 1.5) | 0.019 |
| D'Amico risk categories | |||
| Intermediate risk | 121 (82.8%) | 25 (17.2%) | – |
| High risk | 111 (75%) | 37 (25%) | – |
| NST | 219 (94%) | 57 (92%) | 0.47 |
| Surgical time (min) | 220 (± 53) | 207 (± 38) | 0.034 |
| Estimated blood loss (mL) | 492 (± 254) | 458 (± 277) | 0.410 |
| Pathological stage | 0.5 | ||
| T2 | 124 (55%) | 29 (47%) | – |
| T3a | 53 (23%) | 17 (27%) | – |
| T3b | 48 (21%) | 16 (26%) | – |
| Pathological Gleason | 0.72 | ||
| 2–6 | 22 (10%) | 7 (11.5%) | – |
| 7 | 160 (72%) | 41 (67.2%) | – |
| 8–10 | 39 (17.6%) | 13 (21.3%) | – |
| Catheterization time | 8.8 (± 4.7) | 10.5 (± 6.3) | 0.026 |
| Incontinence, >1 pad/d | 15 | 13 | 0.449 |
DRE, digital rectal examination; NST, nerve sparing technique; PSA, prostatic specific antigen; TURP, transurethral resection of the prostate; TURS, transrectal ultrasound; ULR, urine loss ratio.